Ritonavir: An Extraordinary Example of Conformational Polymorphism

  title={Ritonavir: An Extraordinary Example of Conformational Polymorphism},
  author={John F. Bauer and Stephen G. Spanton and Rodger F. Henry and John Quick and Walter Dziki and William Porter and John Morris},
  journal={Pharmaceutical Research},
AbstractPurpose. In the summer of 1998, Norvir semi-solid capsules supplies were threatened as a result of a new much less soluble crystal form of ritonavir. This report provides characterization of the two polymorphs and the structures and hydrogen bonding network for each form. Methods. Ritonavir polymorphism was investigated using solid state spectroscopy and microscopy techniques including solid state NMR, Near Infrared Spectroscopy, powder X-ray Diffraction and Single crystal X-ray. A… 

Conformational Energy Landscape of the Ritonavir Molecule.

The energy landscape framework is employed to investigate the conformational transitions of an isolated ritonavir molecule and provides mechanistic insight into pathways for cis ↔ trans interconversion at the molecular level and may also help in elucidating the polymorphic transitions in the crystal state.

Novel Polymorph of Favipiravir—An Antiviral Medication

Based on periodic density functional theory calculations, the novel tetragonal polymorph with two interpenetrated H-bonded networks is slightly less stable than the orthorhombic one with the zst topology of the underlying H- bonded net that is in accord with experimentally observed powder X-ray diffraction patterns.

Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties

Inter-relationship between molecular, solid-state and surface structures of the polymorphic forms of ritonavir are quantified in relation to their physical-chemical properties.

Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization

High-throughput crystallization experiments to comprehensively explore ritonavir form diversity found five forms: both known forms and three previously unknown forms, including a metastable polymorph, a hydrate phase, and a formamide solvate.

Packing polymorphism of a conformationally flexible molecule (aprepitant)

This work highlights the structural and thermochemical differences of two modifications of the NK1receptor antagonist aprepitant. Form I° is the stable polymorph and crystallises in the orthorhombic

Ritonavir Form III: A New Polymorph After 24 Years

Rotigotine: Unexpected Polymorphism with Predictable Overall Monotropic Behavior.

Data published in the patents resulting from the discovery of the new polymorph have been used to establish the pressure-temperature phase diagram of the two known solid forms of rotigotine, and it is demonstrated that form II is the stable solid phase and form I is metastable in the entire pressure-Temperature domain.

New Insights into an Old Molecule: Interaction Energies of Theophylline Crystal Forms

The asthma therapeutic theophylline exists in at least three anhydrous polymorphs and a monohydrate. The single-crystal X-ray structure of the high-temperature polymorph form I is presented for the

Olanzapine Form IV: Discovery of a New Polymorphic Form Enabled by Computed Crystal Energy Landscapes

Olanzapine is a polymorphic drug molecule that has been extensively studied, with over 60 structures reported in the Cambridge Structural Database. All anhydrous and solvated forms of olanzapine



Sulfathiazole polymorphism studied by magic-angle spinning NMR.

The spectra presented include those of a newly-recognized form of sulfathiazole sulfate, which are established and discussed in relation to such factors as electronic structure of the aromatic ring, second-order quadrupolar effects originating from the nitrogen nuclei, and hydrogen bonding.

Polymorphism and crystallization behavior of Abbott-79175, a second-generation 5-lipoxygenase inhibitor.

The crystal polymorphism of Abbott-79175, a potent second-generation 5-lipoxygenase inhibitor, has been studied and it is suggested that the relative thermodynamic stability (at least when water was present) in decreasing order is I > II > IA, although I and II are similar energetically.

Pharmaceutical applications of polymorphism.

Polymorphism is the ability of any element or compound to crystallize as more than one distinct crystal species (e.g., carbon as cubic diamond or hexagonal graphite).

Crystal forms of piroxicam pivalate: preparation and characterization of two polymorphs.

Investigation of the polymorphism of piroxicam ester with pivalic acid finds an enantiotropic stability relationship of forms 1 and 2 with a calculated transition point near the ambient temperature.

Solubility behavior of lamivudine crystal forms in recrystallization solvents.

Solution calorimetry data indicated that form I is favored (less soluble) in all solvents studied on the basis of enthalpy alone, which compensates for the enthalpic factors and results in physical stability for form II in these systems.

Demonstration of the terms enantiotropy and monotropy in polymorphism research exemplified by flurbiprofen.

The thermodynamic terms enantiotropy and monotropy are demonstrated by means of solid-state analytical results of polymorphous flurbiprofen (FBP) and the thermodynamic relationships between the three modifications are demonstrated in a semischematic energy/temperature diagram.

Polymorphism and drug availability. Solubility relationships in the methylprednisolone system.

The thermodynamic relationships involving polymorphism and solubility were examined in some detail and applied to experimental results with the methylprednisolone system and indicate that much more energetic crystal forms are probable.

On the polymorphism of pharmaceuticals and other molecular crystals. I

SummaryOn the basis of statistical mechanics, it is shown that the following rules concerning the relative stability of different polymorphic modifications are usually obeyed. (1) The enthalpy of

A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

The design, synthesis, and molecular modeling studies of a novel series of azacyclic ureas, which are inhibitors of human immunodeficiency virus type 1 (HIV-1) protease that incorporate different